Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC) (RESUPEC)
Efficacy and Safety Evaluation of Recombinant Streptokinase and Urokinase in the Treatment of Pulmonary Embolism: A Multi-Center, Randomized Controlled Trial in China
Sponsor: Beijing Chao Yang Hospital
A PHASE4 clinical study on Pulmonary Embolism and Pulmonary Thromboembolism, this trial is completed. The trial is conducted by Beijing Chao Yang Hospital and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE4
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Chao Yang Hospital
- General Hospital of Shenyang Military Region
- Guangdong Institute of Respiratory Disease
- Ningxia Medical University
- Qingdao University
- Shenzhen People's Hospital
- The First Affiliated Hospital of Shanxi Medical University
- Tianjin Medical University General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .